Phase 2 N=18 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease
Primary: Safety: Total Body Water — 45.78; 44.17 Ohms — p=0.024
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Magnetic Seed Localisation of Breast Cancers
Breast Cancer
Primary: Migration of Sentimark Device — 100 percentage of Magseed migrating >10mm
Phase 1 N=20 Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
Rheumatoid Arthritis
Primary: Pharmacokinetic (PK) Parameter: AUClast of Filgotinib — 2389.3; 1981.9 h*ng/mL
Phase 4 N=26 Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
Diabetes Mellitus, Type 2 · Skeletal Muscle Insulin Sensitivity
Primary: Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment — 8.523; 9.592…
Phase 2 N=97 Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
HIV Infections
Primary: Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12…
Phase 2 N=35 A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
Achondroplasia
Primary: Overall Summary of Adverse Events During Initial 6-Month Period — 8; 8; 10; 9 Participants
N/A N=40 Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)
Obstructive Sleep Apnea-hypopnea Syndrome
Primary: Apnea Hypopnea Index (AHI) — 44.77; 47.36; 20.88; 35 events per hour — p=<0.001
Phase 3 N=380 Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
Atopic Dermatitis
Primary: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 98; 33 Participants — p=0.015
Phase 2 N=32 A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Lymphoma
Primary: Percentage of Participants With Overall Response — 25.0 percentage of participants
Phase 1 N=40 cAd3-Marburg Vaccine in Healthy Adults
Marburg Virus Disease
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration — 9; 4; 13; 10 Participants
Phase 4 N=61 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Osteoporosis
Primary: Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion. — -2.1; -4.3; -3.0 percentage change
N/A N=33 Human Factor Validation of Pediatric Mobility Device
Disability Physical
Primary: Cumulative Number of Use Errors Associated With the Usage of the Device According to Labelling — 4; 2 Errors
Phase 2 N=20 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Lip and Oral Cavity Squamous Cell Carcinoma · Oral Cavity Verrucous Carcinoma · Precancerous Condition
Primary: Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
Phase 2 N=215 Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Chronic Myelogenous Leukemia
Primary: Percentage of Patients Who Are in MMR (Major Molecular Response) at 48 Weeks After Starting the Treatment-free Remission (TFR) Phase — 51.6 Percentage of participants
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL